Alkem Launches 'PRAYAS': A Bold Step Toward Accessible Cancer Care - Video

In a significant patient-centric move, Alkem Laboratories Ltd., one of India's largest pharmaceutical companies, has launched PRAYAS- a dedicated Patient Assistance and EMI Support Program aimed at improving access to life-saving biosimilars for cancer patients across the country.

PRAYAS is currently being rolled out for patients requiring Bevacizumab 100mg and 400mg with brand name ADVAMAB, a key therapy in multiple cancers, including colorectal, ovarian, and non-small cell lung cancer, among others. The program offers:

• 0% Interest EMI Options – Enabling timely initiation and continuation of therapy
• Need-Based Financial Assistance – For patients from low-income backgrounds
• Customizable Support – Vial support, financial aid, or both depending on patient profile

Enrollment into the PRAYAS program is simple and accessible—patients or caregivers can write to prayas@rxcs.in, call the dedicated helpline at +91 9240205435, or register via the online portal at https://leads.icanheal.in/alkem

The launch of PRAYAS reflects Alkem’s commitment to bridging the affordability gap in oncology care and the belief that no patient should be denied access to essential treatment due to financial constraints.

The company emphasized that PRAYAS is not just a support initiative but a commitment to ensuring that lifesaving therapies reach patients in need without delay or compromise, reflecting the company's belief that compassionate care is as vital as scientific innovation.

This follows Alkem’s earlier milestone a flagship biosimilar support initiative launched alongside CETUXA (Cetuximab), reinforcing its commitment to affordability and accessibility in oncology care.

Through its R&D-driven biosimilar arm, Enzene Biosciences Ltd., Alkem is reinforcing its commitment to easing the financial burden of cancer care, particularly for patients from economically weaker sections of society.